AVT vs RELY

AVT's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial health. The Graham Number suggests a defensive fair value of $59.95, implying the current price of $50.83 is slightly undervalued, though growth-based intrinsic value is much lower at $18.76. Profitability metrics are weak, with low margins and declining earnings, but the balance sheet shows strength via a solid current ratio and moderate leverage. Despite mixed signals, the stock appears fairly valued with moderate risks and limited near-term catalysts.

RELY exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a robust liquidity profile (Current Ratio 3.30). While the company is successfully transitioning to profitability with explosive YoY EPS growth and consistent earnings beats, it trades at a significant premium to its Graham Number ($5.36) and Intrinsic Value ($2.17). This valuation gap is partially mitigated by a low Forward P/E of 13.08, suggesting high expected earnings growth. However, aggressive insider selling totaling $195.56M creates a significant headwind that offsets the bullish analyst consensus.